Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19. Issue 2 (April 2023)

• Record Type: Journal Article
• Authors: Lemaitre, Florian; Budde, Klemens; Van Gelder, Teun; Bergan, Stein; Lawson, Roland; Noceti, Ofelia; Venkataramanan, Raman; Elens, Laure; Moes, Dirk Jan A. R.; Hesselink, Dennis A.; Pawinski, Tomasz; Johnson-Davis, Kamisha L.; De Winter, Brenda C. M.; Pattanaik, Smita; Brunet, Mercè; Masuda, Satohiro; Langman, Loralie J.
• Is Part Of: Therapeutic drug monitoring. Volume 45:Issue 2(2023)
• Page Start: 191
• Page End: 199
• Publication Date: 2023-04
• Subjects: drug–drug interactions -- transplantation -- calcineurin inhibitors -- mTOR inhibitors -- tacrolimus; Pharmacokinetics -- Periodicals; Patient monitoring -- Periodicals; Drugs -- Analysis -- Periodicals; Body fluids -- Analysis -- Periodicals; Drug Therapy -- Periodicals; Monitoring, Physiologic -- Periodicals; Pharmacology -- Periodicals; 615.7
• DOI: 10.1097/FTD.0000000000001014
• Languages: English
• ISSNs: 0163-4356

Abstract

Abstract: Nirmatrelvir/ritonavir (Paxlovid) consists of a peptidomimetic inhibitor (nirmatrelvir) of the SARS-CoV-2 main protease and a pharmacokinetic enhancer (ritonavir). It is approved for the treatment of mild-to-moderate COVID-19. This combination of nirmatrelvir and ritonavir can mediate significant and complex drug–drug interactions (DDIs), primarily due to the ritonavir component. Indeed, ritonavir inhibits the metabolism of nirmatrelvir through cytochrome P450 3A (CYP3A) leading to higher plasma concentrations and a longer half-life of nirmatrelvir. Coadministration of nirmatrelvir/ritonavir with immunosuppressive drugs (ISDs) is particularly challenging given the major involvement of CYP3A in the metabolism of most of these drugs and their narrow therapeutic ranges. Exposure of ISDs will be drastically increased through the potent ritonavir-mediated inhibition of CYP3A, resulting in an increased risk of adverse drug reactions. Although a decrease in the dosage of ISDs can prevent toxicity, an inappropriate dosage regimen may also result in insufficient exposure and a risk of rejection. Here, we provide some general recommendations for therapeutic drug monitoring of ISDs and dosing recommendations when coadministered with nirmatrelvir/ritonavir. Particularly, tacrolimus should be discontinued, or patients should be given a microdose on day 1, whereas cyclosporine dosage should be reduced to 20% of the initial dosage during the antiviral treatment. Dosages of mammalian target of rapamycin inhibitors (m-TORis) should also be adjusted while dosages of mycophenolic acid and corticosteroids are expected to be less impacted.